You just read:

For Renal Cell Carcinoma, Most Surveyed European Oncologists Would Switch From Sutent to an Emerging Therapy if it Extended Progression-Free Survival by at Least an Additional Two to Three Months

News provided by

Decision Resources

Oct 25, 2010, 08:00 ET